Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Jason B. Liu, Vernissia Tam, Mazen S. Zenati, Danielle Schwartz, Areej Ali, Carissa A. Low, Lillian J. Smith, Herbert J. Zeh, Amer H. Zureikat, Melissa E. Hogg
Publikováno v:
HPB. 24:1659-1667
Robotic-assisted pancreatectomy continues to proliferate despite limited evidence supporting its benefits from the patient's perspective. We compared patient-reported outcomes (PROs) between patients undergoing robotic and open pancreatectomies.PROs,
Autor:
Nathan Bahary, Caroline J. Rieser, Herbert J. Zeh, Mazen S. Zenati, Kenneth K. Lee, Amer H. Zureikat, Hao Liu, Aatur D. Singhi, Amr Al-abbas, Melissa E. Hogg
Publikováno v:
Ann Surg Oncol
BACKGROUND: Neoadjuvant therapy (NAT) is increasingly utilized for pancreatic cancer, however the added benefit of adjuvant therapy (AT) in this setting is unknown. We hypothesized that the magnitude of CA19-9 response to NAT can guide the need for f
Autor:
Ahmad Hamad, Melissa E. Hogg, Caroline J. Rieser, Amr I. Al Abbas, Amer H. Zureikat, Nathan Bahary, Mazen S. Zenati, Herbert J. Zeh
Publikováno v:
Annals of surgical oncology. 25(12)
Serum carbohydrate antigen 19-9 (CA19-9) correlates with response to therapy and overall survival (OS) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aimed to define the chronologic relationship between CA19-9 elevation and rad
Autor:
Nathan Bahary, Jennifer Steve, Herbert J. Zeh, David L. Bartlett, Amer H. Zureikat, Brian A. Boone, Melissa E. Hogg, Mazen S. Zenati, Aatur D. Singhi
Publikováno v:
Annals of Surgical Oncology. 21:4351-4358
Baseline carbohydrate antigen 19-9 (CA 19-9) is a useful prognostic marker in pancreatic ductal adenocarcinoma (PDA); however, data on the significance of a change in CA 19-9 following neoadjuvant therapy are lacking.All patients receiving neoadjuvan
Autor:
Kenneth K.W. Lee, David L. Bartlett, James F. Pingpank, Amer H. Zureikat, Haroon A. Choudry, Matthew P. Holtzman, Mazen S. Zenati, Lekshmi Ramalingam, Heather Jones, Herbert J. Zeh, Joshua Winer, Steven A. Ahrendt
Publikováno v:
Annals of Surgical Oncology. 21:1456-1462
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) for peritoneal carcinomatosis (PC) of colorectal origin increases survival (OS) compared to systemic chemotherapy alone. Signet ring histology demonstrates aggressive
Autor:
Haroon A. Choudry, Matthew P. Holtzman, Steven A. Ahrendt, David L. Bartlett, Heather Jones, Herbert J. Zeh, Joshua Winer, Arun Mavanur, Deepa Magge, Amer H. Zureikat, Kenneth K.W. Lee, Mazen S. Zenati, Lekshmi Ramalingam, James F. Pingpank
Publikováno v:
Annals of Surgical Oncology. 21:1448-1455
Background. Peritoneal carcinomatosis from gastric cancer (GPC) responds poorly to systemic chemotherapy. Limited published data demonstrate improved outcomes after aggressive locoregional therapies. We assessed the efficacy of cytoreductive surgery
Autor:
Anne Germain, Jason L. Sperry, Andrew B. Peitzman, Mazen S. Zenati, Amy S. Clontz, Dederia H. Nicholas, Louis H. Alarcon, Eileen Roach
Publikováno v:
Journal of Trauma and Acute Care Surgery. 72:629-637
Posttraumatic stress disorder (PTSD) is associated with significant morbidity following injury. The incidence and risk factors for PTSD are not well described in the civilian trauma population. We proposed to screen all trauma patients in the outpati
Autor:
Lekshmi Ramalingam, Patrick L. Wagner, David L. Bartlett, James F. Pingpank, Steven A. Ahrendt, Herbert J. Zeh, Matthew P. Holtzman, Haroon A. Choudry, Frances Austin, Aaron Jaech, Arun Mavanur, Amer H. Zureikat, Heather L. Jones, Mazen S. Zenati
Publikováno v:
Annals of surgical oncology. 23(5)
Patients with peritoneal carcinomatosis (PC) of appendiceal origin demonstrate variable oncologic outcomes, despite aggressive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS–HIPEC). We sought to devise a prognostic risk st
Autor:
Steven A. Ahrendt, Frances Austin, Amer H. Zureikat, Heather Jones, Lekshmi Ramalingam, Magesh Sathaiah, Matthew P. Holtzman, Haroon A. Choudry, Arun Mavanur, David L. Bartlett, Herbert J. Zeh, Deepa Magge, Mazen S. Zenati, James F. Pingpank
Most patients with malignant peritoneal mesothelioma (MPM) present with late-stage, unresectable disease that responds poorly to systemic chemotherapy while, at the same time, effective targeted therapies are lacking. We assessed the efficacy of cyto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1a232c1c71e0a2bf34234e886ef70a
https://europepmc.org/articles/PMC4100549/
https://europepmc.org/articles/PMC4100549/
Autor:
L Martin, Kyle Soltys, Motaz Al Samman, Nico Shaefer, George V. Mazariegos, Kareem Abu-Elmagd, Beverly Kosmach-Park, Mazen S. Zenati, Rakesh Sindhi, Geoffrey J. Bond, Darlene Koritsky, Hiroshi Sogawa, John G. Lunz, Noriko Murase, Guilherme Costa, Maureen Emerling
Publikováno v:
Annals of surgery. 256(3)
OBJECTIVE To assess long-term survival, graft function, and health-related quality of life (QOL) after visceral transplantation. BACKGROUND Despite continual improvement in early survival, the long-term therapeutic efficacy of visceral transplantatio